NOVEL THERAPIES TO ENHANCE ANTI-TUMOUR IMMUNITY

Grant number: 1139626 | Funding period: 2018 - 2021

Completed

Abstract

Immunotherapy is a new approach to treat cancer, and works by promoting the immune system to attack cancer. Immunotherapies, such as checkpoint blockade and adoptive T cell therapy, are proving to be very successful in certain human cancers. However, combining immunotherapy with drugs that cause cancer cell death may be more effective. This project will investigate the potential of combining immunotherapy with a novel anti-cancer drug, in order to develop more effective treatments for cancer.

Related publications (7)

Scholarly works icon

NKG7 Enhances CD8 T Cell Synapse Efficiency to Limit Inflammation

Emily J Lelliott, Kelly M Ramsbottom, Mark R Dowling, Carolyn Shembrey, Tahereh Noori, Conor J Kearney, Jessica Michie, Ian A Parish, Margaret A Jordan, Alan G Baxter, Neil D Young, Amelia J Brennan, Jane Oliaro

2022-07-06

Cytotoxic lymphocytes are essential for anti-tumor immunity, and for effective responses to cancer immunotherapy. Natural killer c..

Scholarly works icon

Unleashing TNF cytotoxicity to enhance cancer immunotherapy

Andrew J Freeman, Conor J Kearney, John Silke, Jane Oliaro

2021-11-24

Tumor necrosis factor (TNF) is a proinflammatory cytokine that is produced and secreted by cytotoxic lymphocytes upon tumor target..

Scholarly works icon

CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory

Emily J Lelliott, Isabella Y Kong, Magnus Zethoven, Kelly M Ramsbottom, Luciano G Martelotto, Deborah Meyran, Joe Jiang Zhu, Matteo Costacurta, Laura Kirby, Jarrod J Sandow, Lydia Lim, Pilar M Dominguez, Izabela Todorovski, Nicole M Haynes, Paul A Beavis, Paul J Neeson, Edwin D Hawkins, Grant A McArthur, Ian A Parish, Ricky W Johnstone

2021-10-01

Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are an approved treatment for hormone receptor-positive brea..

Scholarly works icon

HOIP limits anti-tumor immunity by protecting against combined TNF and IFN-gamma-induced apoptosis

Andrew J Freeman, Stephin J Vervoort, Jessica Michie, Kelly M Ramsbottom, John Silke, Conor J Kearney, Jane Oliaro

2021-09-01

The success of cancer immunotherapy is limited to a subset of patients, highlighting the need to identify the processes by which t..

Scholarly works icon

Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma

Emily J Lelliott, Grant A McArthur, Jane Oliaro, Karen E Sheppard

2021-05-07

The recent advent of targeted and immune-based therapies has revolutionized the treatment of melanoma and transformed outcomes for..

Scholarly works icon

Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma

Emily J Lelliott, Stefano Mangiola, Kelly M Ramsbottom, Magnus Zethoven, Lydia Lim, Peter KH Lau, Amanda J Oliver, Luciano G Martelotto, Laura Kirby, Claire Martin, Riyaben P Patel, Alison Slater, Carleen Cullinane, Anthony T Papenfuss, Nicole M Haynes, Grant A McArthur, Jane Oliaro, Karen E Sheppard

2021-02-01

Combined inhibition of BRAF, MEK, and CDK4/6 is currently under evaluation in clinical trials for patients with melanoma harboring..

Scholarly works icon

The Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein Antagonists in Cancer Immunotherapy

Jessica Michie, Conor Kearney, Edwin D Hawkins, John Silke, Jane Oliaro

2020-01-14

One of the hallmarks of cancer cells is their ability to evade cell death via apoptosis. The inhibitor of apoptosis proteins (IAPs..